Remus Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Operating Revenue	4,561	2,125	450.27	247.17	184.18	119.19
Other Revenue	3.59	3.59	1.05	-	3.9	5
Revenue	4,565	2,129	451.32	247.17	188.08	124.19
Revenue Growth (YoY)	-	371.63%	82.59%	31.42%	51.44%	-
Cost of Revenue	3,827	1,644	214.69	122.81	115.04	70.44
Gross Profit	738.12	484.2	236.63	124.36	73.04	53.75
Selling, General & Admin	100.15	74.23	54.7	34.24	29.95	30.67
Other Operating Expenses	236.94	121.35	70.45	46.32	29.71	12.67
Operating Expenses	345.66	204.54	129.92	82.1	61.41	44.39
Operating Income	392.45	279.65	106.71	42.26	11.63	9.36
Interest Expense	-10.78	-4.49	-2.04	-0.78	-0.29	-0.31
Interest & Investment Income	22.55	22.55	3.48	2.45	0.69	-
Currency Exchange Gain (Loss)	5.73	5.73	6.24	2.22	0.53	2.01
Other Non Operating Income (Expenses)	11.87	-0.26	-0.26	-0.09	-0.06	-0.11
EBT Excluding Unusual Items	443.43	303.19	114.14	46.06	12.5	10.94
Gain (Loss) on Sale of Investments	-	-	-	0.08	1.08	-
Gain (Loss) on Sale of Assets	15.1	15.1	-	-	-	-
Pretax Income	458.53	318.29	114.14	46.13	13.58	10.94
Income Tax Expense	67.31	58.52	29.11	11.79	3.32	2.82
Earnings From Continuing Operations	391.22	259.77	85.03	34.34	10.26	8.12
Minority Interest in Earnings	-92.21	-44.4	-	-	-	-
Net Income	299.01	215.37	85.03	34.34	10.26	8.12
Net Income to Common	299.01	215.37	85.03	34.34	10.26	8.12
Net Income Growth	-	153.29%	147.60%	234.77%	26.39%	-
Shares Outstanding (Basic)	6	6	4	4	4	4
Shares Outstanding (Diluted)	6	6	4	4	4	4
Shares Change (YoY)	8.32%	38.79%	2.10%	-	-	-
EPS (Basic)	50.73	38.00	20.82	8.59	2.56	2.03
EPS (Diluted)	50.73	38.00	20.82	8.59	2.56	2.03
EPS Growth	-	82.51%	142.51%	234.77%	26.39%	-
Free Cash Flow	-	29.67	25.81	49.67	27.72	7.43
Free Cash Flow Per Share	-	5.23	6.32	12.42	6.93	1.86
Dividend Per Share	-	1.500	0.500	-	-	-
Dividend Growth	-	200.00%	-	-	-	-
Gross Margin	16.17%	22.75%	52.43%	50.31%	38.83%	43.28%
Operating Margin	8.60%	13.14%	23.64%	17.10%	6.18%	7.53%
Profit Margin	6.55%	10.12%	18.84%	13.89%	5.45%	6.54%
Free Cash Flow Margin	-	1.39%	5.72%	20.09%	14.74%	5.99%
EBITDA	402.67	288.39	111.36	43.81	13.38	10.42
EBITDA Margin	8.82%	13.55%	24.67%	17.73%	7.11%	8.39%
D&A For EBITDA	10.21	8.73	4.64	1.55	1.75	1.06
EBIT	392.45	279.65	106.71	42.26	11.63	9.36
EBIT Margin	8.60%	13.14%	23.64%	17.10%	6.18%	7.53%
Effective Tax Rate	14.68%	18.38%	25.50%	25.56%	24.47%	25.81%
Revenue as Reported	4,628	2,179	466.05	254.37	192.25	127.69
Advertising Expenses	-	-	-	-	-	2.08

Source: S&P Capital IQ. Standard template. Financial Sources.